Poseida Therapeutics (PSTX) Competitors $3.08 +0.15 (+5.12%) (As of 11/8/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PSTX vs. ADAP, STRO, AGEN, DTIL, PASG, ZYME, PAHC, CRGX, AUTL, and CGEMShould you be buying Poseida Therapeutics stock or one of its competitors? The main competitors of Poseida Therapeutics include Adaptimmune Therapeutics (ADAP), Sutro Biopharma (STRO), Agenus (AGEN), Precision BioSciences (DTIL), Passage Bio (PASG), Zymeworks (ZYME), Phibro Animal Health (PAHC), CARGO Therapeutics (CRGX), Autolus Therapeutics (AUTL), and Cullinan Therapeutics (CGEM). These companies are all part of the "medical" sector. Poseida Therapeutics vs. Adaptimmune Therapeutics Sutro Biopharma Agenus Precision BioSciences Passage Bio Zymeworks Phibro Animal Health CARGO Therapeutics Autolus Therapeutics Cullinan Therapeutics Adaptimmune Therapeutics (NASDAQ:ADAP) and Poseida Therapeutics (NASDAQ:PSTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking, profitability and dividends. Which has higher earnings and valuation, ADAP or PSTX? Adaptimmune Therapeutics has higher earnings, but lower revenue than Poseida Therapeutics. Poseida Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$60.28M3.30-$113.87M-$0.35-2.22Poseida Therapeutics$64.70M4.40-$123.43M-$1.19-2.46 Does the MarketBeat Community favor ADAP or PSTX? Adaptimmune Therapeutics received 275 more outperform votes than Poseida Therapeutics when rated by MarketBeat users. However, 67.86% of users gave Poseida Therapeutics an outperform vote while only 62.73% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformAdaptimmune TherapeuticsOutperform Votes31362.73% Underperform Votes18637.27% Poseida TherapeuticsOutperform Votes3867.86% Underperform Votes1832.14% Do analysts rate ADAP or PSTX? Adaptimmune Therapeutics presently has a consensus price target of $3.38, indicating a potential upside of 335.49%. Poseida Therapeutics has a consensus price target of $15.00, indicating a potential upside of 411.95%. Given Poseida Therapeutics' higher probable upside, analysts clearly believe Poseida Therapeutics is more favorable than Adaptimmune Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Poseida Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ADAP or PSTX? Adaptimmune Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, Poseida Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Do institutionals and insiders believe in ADAP or PSTX? 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 46.9% of Poseida Therapeutics shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by insiders. Comparatively, 2.9% of Poseida Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ADAP or PSTX more profitable? Adaptimmune Therapeutics has a net margin of -51.25% compared to Poseida Therapeutics' net margin of -127.48%. Adaptimmune Therapeutics' return on equity of -116.80% beat Poseida Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-51.25% -116.80% -25.02% Poseida Therapeutics -127.48%-121.01%-39.66% Does the media favor ADAP or PSTX? In the previous week, Poseida Therapeutics had 2 more articles in the media than Adaptimmune Therapeutics. MarketBeat recorded 3 mentions for Poseida Therapeutics and 1 mentions for Adaptimmune Therapeutics. Adaptimmune Therapeutics' average media sentiment score of 0.48 beat Poseida Therapeutics' score of 0.25 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptimmune Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Poseida Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAdaptimmune Therapeutics beats Poseida Therapeutics on 11 of the 17 factors compared between the two stocks. Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Get Poseida Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTX vs. The Competition Export to ExcelMetricPoseida TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$284.59M$3.20B$5.27B$8.82BDividend YieldN/A1.76%4.64%4.01%P/E Ratio-2.4612.58119.9616.14Price / Sales4.40325.241,328.52102.19Price / CashN/A147.8838.8934.14Price / Book2.715.265.825.78Net Income-$123.43M-$42.25M$118.30M$224.20M7 Day Performance18.62%15.71%4.08%4.17%1 Month Performance14.01%22.78%11.05%7.85%1 Year Performance28.51%53.27%39.14%28.75% Poseida Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTXPoseida Therapeutics3.7232 of 5 stars$3.08+5.1%$15.00+387.0%+20.1%$299.16M$64.70M-2.59260Analyst ForecastNews CoverageGap UpHigh Trading VolumeADAPAdaptimmune Therapeutics2.2714 of 5 stars$0.80+10.2%N/A+30.4%$204.54M$60.28M-2.29449Upcoming EarningsSTROSutro Biopharma4.2082 of 5 stars$3.55+9.2%N/A+58.8%$290.96M$153.73M-1.94240Upcoming EarningsAGENAgenus3.8283 of 5 stars$4.05-3.6%N/A-76.0%$87.36M$156.31M-0.36389Upcoming EarningsDTILPrecision BioSciences3.7818 of 5 stars$9.02+5.4%N/A-28.0%$65.22M$48.73M43.39200Analyst RevisionPASGPassage Bio3.418 of 5 stars$0.63+2.3%N/A-5.7%$38.88MN/A-0.47130Upcoming EarningsNews CoverageZYMEZymeworks2.1433 of 5 stars$13.28-3.1%N/A+127.5%$943.54M$76.01M-8.85290Analyst UpgradeAnalyst RevisionPAHCPhibro Animal Health4.3974 of 5 stars$23.18+0.3%N/A+94.2%$938.79M$1.02B386.401,940Dividend AnnouncementNews CoverageCRGXCARGO Therapeutics1.9868 of 5 stars$20.37+4.5%N/AN/A$935.09MN/A-0.40116Positive NewsAUTLAutolus Therapeutics2.9945 of 5 stars$3.50+3.9%N/A+9.8%$931.32M$1.70M-3.02330Upcoming EarningsCGEMCullinan Therapeutics1.8985 of 5 stars$15.78+1.5%N/A+58.0%$914.92M$18.94M-5.1630Upcoming EarningsInsider SellingNews Coverage Related Companies and Tools Related Companies ADAP Competitors STRO Competitors AGEN Competitors DTIL Competitors PASG Competitors ZYME Competitors PAHC Competitors CRGX Competitors AUTL Competitors CGEM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PSTX) was last updated on 11/8/2024 by MarketBeat.com Staff From Our Partners“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCan Trump Make Housing Great Again?Trump won. But can he undo the damage the Democrats have inflicted on this nation? Under Biden, inflatio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Poseida Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
